New insider activity at 10x Genomics ( (TXG) ) has taken place on August 26, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving 10x Genomics stock, CEO Serge Saxonov sold 9,348 shares valued at $128,815. CFO Adam Taich offloaded 22,315 shares for $307,500, while President and Chief Scientific Officer Benjamin J. Hindson parted with 7,486 shares, amounting to $103,157.
Recent Updates on TXG stock
In the last 24 hours, 10x Genomics has seen significant developments that have influenced its stock price targets. The company held its Q2 earnings call, revealing strong performances in China and spatial consumables, a favorable settlement with Bruker, and strategic acquisitions, though these were offset by challenges in capital expenditure, decreased revenue in key regions, and uncertainties in academic funding. Analysts have responded to these mixed signals with varied price target adjustments. Canaccord raised its price target due to optimism about the company’s potential to reaccelerate growth and attractive current share levels. UBS increased its target, acknowledging a quarterly beat but noting a persistently muted environment. Deutsche Bank also raised its target, maintaining a Hold rating amidst macroeconomic challenges. These changes reflect a cautious optimism about 10x Genomics’ strategic positioning and growth prospects despite existing hurdles.
Spark’s Take on TXG Stock
According to Spark, TipRanks’ AI Analyst, TXG is a Neutral.
10x Genomics’ stock score is primarily influenced by its financial performance and technical analysis. While the company shows potential with improving cash flow and positive market momentum, profitability challenges and a negative P/E ratio weigh heavily on its valuation. The technical indicators suggest potential for price appreciation, but the financial fundamentals and valuation concerns limit the overall score.
To see Spark’s full report on TXG stock, click here.
More about 10x Genomics
YTD Price Performance: -0.85%
Average Trading Volume: 3,740,093
Technical Sentiment Signal: Sell
Current Market Cap: $1.75B